2.24
0.44%
-0.010
After Hours:
2.23
-0.01
-0.45%
Checkpoint Therapeutics Inc stock is traded at $2.24, with a volume of 197.41K.
It is down -0.44% in the last 24 hours and down -4.68% over the past month.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
See More
Previous Close:
$2.25
Open:
$2.25
24h Volume:
197.41K
Relative Volume:
0.51
Market Cap:
$100.84M
Revenue:
$103.00K
Net Income/Loss:
$-51.85M
P/E Ratio:
-0.4125
EPS:
-5.43
Net Cash Flow:
$-47.59M
1W Performance:
-5.08%
1M Performance:
-4.68%
6M Performance:
+9.27%
1Y Performance:
+31.76%
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Name
Checkpoint Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
95 SAWYER ROAD, WALTHAM, NY
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-14-22 | Resumed | B. Riley Securities | Buy |
Jun-09-21 | Initiated | B. Riley Securities | Buy |
Jan-20-21 | Initiated | Cantor Fitzgerald | Overweight |
May-29-19 | Initiated | Lake Street | Buy |
Dec-08-17 | Initiated | H.C. Wainwright | Buy |
Checkpoint Therapeutics Inc Stock (CKPT) Latest News
A Closer Look at Checkpoint Therapeutics Inc (CKPT) Stock Gains - The InvestChronicle
Market Resilience: Checkpoint Therapeutics Inc (CKPT) Finishes Weak at 2.22, Down -5.93 - The Dwinnex
Do investors need to be concerned about Checkpoint Therapeutics Inc (CKPT)? - US Post News
Examining the Potential Price Growth of Checkpoint Therapeutics Inc (CKPT) - Knox Daily
Checkpoint Therapeutics Inc (CKPT) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
HC Wainwright Reaffirms Buy Rating for Checkpoint Therapeutics (NASDAQ:CKPT) - MarketBeat
Checkpoint Therapeutics reports promising cosibelimab trial results By Investing.com - Investing.com Canada
Checkpoint Therapeutics reports promising cosibelimab trial results - Investing.com
Checkpoint Therapeutics reports promising cosibelimab trial results - Investing.com India
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - StockTitan
Checkpoint Therapeutics Announces Cosibelimab Longer-Term - GlobeNewswire
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024 - Morningstar
Head to Head Analysis: Checkpoint Therapeutics (NASDAQ:CKPT) & Neoleukin Therapeutics (NASDAQ:NLTX) - Defense World
A company insider recently sold 24,610 shares of Checkpoint Therapeutics Inc [CKPT]. Should You Sale? - Knox Daily
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success - Seeking Alpha
Vanguard Group Inc. Purchases 369,586 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - MarketBeat
EMulate Therapeutics Inc. Announces Publication of Pre-Clinical Mouse Model Demonstrating Direct Evidence of Immune Checkpoint Receptor Knock-Down in a Mouse Glioblastoma Model - Business Wire
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Up 7.4% in July - MarketBeat
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock - Yahoo Finance
Thinking about buying stock in Innoviz Technologies, 22nd Centur - GuruFocus.com
Equities Analysts Issue Forecasts for Checkpoint Therapeutics, Inc.'s Q3 2024 Earnings (NASDAQ:CKPT) - MarketBeat
Q3 2024 Earnings Estimate for Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Issued By HC Wainwright - Defense World
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit - Longview News-Journal
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Checkpoint Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesCKPT - Longview News-Journal
Checkpoint Therapeutics (NASDAQ:CKPT) Price Target Lowered to $20.00 at HC Wainwright - Defense World
CKPT Stock Earnings: Checkpoint Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
Checkpoint Therapeutics (NASDAQ:CKPT) Given New $20.00 Price Target at HC Wainwright - MarketBeat
CKPT Stock Earnings: Checkpoint Therapeutics Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - ForexTV.com
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates - StockTitan
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Holdings Cut by B. Riley Wealth Advisors Inc. - Defense World
Analysts review Checkpoint Therapeutics Inc’s rating - Knox Daily
Checkpoint Therapeutics Inc (CKPT)’s stock price range in the last year - US Post News
Insider Sale Alert: Checkpoint Therapeutics Inc [CKPT] – Is it Time to sell? - Knox Daily
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm - Kilgore News Herald
Market Resilience: Checkpoint Therapeutics Inc (CKPT) Finishes Weak at 2.42, Down -5.84 - The Dwinnex
CKPT Investors Have Opportunity to Lead Checkpoint Therapeutics, Inc. Securities Fraud Lawsuit - Kilgore News Herald
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class ActionCKPT - Kilgore News Herald
Boehringer inks $1.3B acquisition of Nerio and its preclinical checkpoint inhibitors - Fierce Biotech
CKPT’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Checkpoint Therapeutics Shares Rise After FDA Accepts Resubmission of Cosibelimab - MarketWatch
Checkpoint Therapeutics Announces FDA Acceptance of BLA - GlobeNewswire
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - StockTitan
Checkpoint Therapeutics Inc (CKPT) may enjoy gains as insiders got busy in the recent days - Knox Daily
Recent Insider Activity Could Benefit Checkpoint Therapeutics Inc (CKPT) - Knox Daily
Checkpoint Therapeutics’ (CKPT) Buy Rating Reaffirmed at HC Wainwright - Defense World
A closer look at Checkpoint Therapeutics Inc (CKPT)’s stock price trends - US Post News
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Buy Rating from HC Wainwright - MarketBeat
Checkpoint Therapeutics Inc Stock (CKPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):